Resultaten visas 1 - 10 / 29
resultat / per sida
Vilka publikationsuppgifter finns i tjänsten?
Publikationens namn
Upphovspersoner
Publikationskanal
År

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Referentgranskad
Öppen tillgång
DOI
10.1186/s13148-019-0781-3
Facciotto, Chiara; Casado, Julia; Turunen, Laura; Leivonen, Suvi-Katri; Tumiati, Manuela; Rantanen, ...
Clinical epigenetics2019

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

Referentgranskad
DOI
10.1111/j.1600-0609.2010.01541.x
Riihijarvi, Sari; Taskinen, Minna; Jerkeman, Mats; Leppä, Sirpa Marianne
European journal of haematology2011

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Referentgranskad
Öppen tillgång
DOI
10.1182/bloodadvances.2020001518
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-...
Blood advances2020

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

Referentgranskad
DOI
10.3109/10428194.2012.672736
Räty, Riikka; Honkanen, Tuomo; Jantunen, Esa; Jyrkkio, Sirkku; Karjalainen-Lindsberg, Marja-Liisa; K...
Leukemia & lymphoma2012

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE):a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Referentgranskad
Öppen tillgång
DOI
10.1016/S0140-6736(24)00184-3
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; ...
The Lancet2024

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
Öppen tillgång
DOI
10.3390/cancers15041341
Kuitunen, Hanne K; Rönkä, Aino LK; Sonkajärvi, Eila M; Isokangas, Juha-Matti; Pyörälä, Marja; Palosa...
Cancers2023

Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
Kuitunen HK; Rönkä AL; Sonkajärvi EM; Isokangas J; Pyörälä M; Palosaari KA; Jokimäki AS; Partanen AE...
Cancers2023

Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
Kuitunen HK; Rönkä AL; Sonkajärvi EM; Isokangas J; Pyörälä M; Palosaari KA; Jokimäki AS; Partanen AE...
Cancers2023

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Referentgranskad
Öppen tillgång
DOI
10.1016/j.clml.2021.06.021
Matasar, Matthew J.; Dreyling, Martin; Leppä, Sirpa; Santoro, Armando; Pedersen, Michael; Buvaylo, V...
Clinical lymphoma myeloma and leukemia2021

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Referentgranskad
DOI
10.1200/JCO.2015.65.7163
Sarkozy, Clementine; Trneny, Marek; Xerri, Luc; Wickham, Nick; Feugier, Pierre; Leppa, Sirpa; Brice,...
Journal of clinical oncology2016

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Referentgranskad
Öppen tillgång
DOI
10.1186/s13148-019-0781-3
2019

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

Referentgranskad
DOI
10.1111/j.1600-0609.2010.01541.x
2011

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Referentgranskad
Öppen tillgång
DOI
10.1182/bloodadvances.2020001518
2020

Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

Referentgranskad
DOI
10.3109/10428194.2012.672736
2012

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE):a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Referentgranskad
Öppen tillgång
DOI
10.1016/S0140-6736(24)00184-3
2024

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
Öppen tillgång
DOI
10.3390/cancers15041341
2023

Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
2023

Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Referentgranskad
2023

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Referentgranskad
Öppen tillgång
DOI
10.1016/j.clml.2021.06.021
2021

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Referentgranskad
DOI
10.1200/JCO.2015.65.7163
2016